Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC’s First Committee Recommends Approval for OAB Drug Neoxy Tape
March 11, 2013
- Health Sciences Council to Discuss Protocol for Clinical Trial Using iPS Cells
March 11, 2013
- Kyoto Medical Association Vice President Hideki Adachi Says Drug Makers Should Closely Verify NHI Prices and Development Costs of Each Drug
March 8, 2013
- Drug Safety Monitoring Program of RMPs to Be Announced via PMDA’s Website: PFSB Notification
March 7, 2013
- Over 40% of Preliminary Meetings Proceed to Face-to-Face Consultation Meetings in Regulatory Strategy Consultation Services: Report
March 7, 2013
- MHLW to Announce Revised GVP, GPSP Ordinances “Early Next Week”: Director Tawaragi of PFSB
March 6, 2013
- MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
- MHLW Aims to Submit Bill to Amend PAL During Current Diet Session: PFSB Director-General Jun Ebata
March 6, 2013
- PAFSC Second Committee to Discuss Pfizer’s Xeljanz and Bayer’s Stivarga on March 13
March 5, 2013
- PAFSC First Committee on New Drugs to Discuss Approval of New Parkinson’s Disease Agent and DPP-4 Inhibitor Onglyza
March 5, 2013
- Health and Education Ministries along with Drug Makers to Start Intractable Disease Research using iPS Cells
March 5, 2013
- Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
- Generic Share by Volume Rose to 28.7% in September 2012, MHLW Reports
March 4, 2013
- Tokyo District Court Dismisses Takeda’s Actos Litigation Against 10 Companies; No Appeal Planned
March 4, 2013
- Japan’s Average Drug Price is 1.44 Times Higher than Europe: MHLW Tally
March 1, 2013
- MHLW’s Health and Medical Strategy HQ Aims to Draft a Final Plan by May
February 28, 2013
- Pharmacies’ Generic Drug Dispensing Rate Rises to 29.4%: Survey Reported to CSIMC
February 28, 2013
- 5 Years Too Long to Achieve Reference Generic Share Target of 60%: Bill Payer Reps at CSIMC Subcommittee
February 28, 2013
- Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium
February 28, 2013
- Participation in TPP Talks “Will Not Damage” Japan’s Universal Health Insurance System: Health Minister Tamura
February 27, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…